fungiska
fungiska Uses, Dosage, Side Effects, Food Interaction and all others data.
fungiska (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
fungiska is an antifungal drug, and belongs to a new class termed the echinocandins. It is used to treat Aspergillus and Candida infection, and works by inhibiting cell wall synthesis. Antifungals in the echinocandin class inhibit the synthesis of glucan in the cell wall, probably via the enzyme 1,3-beta glucan synthase. There is a potential for resistance development to occur, however in vitro resistance development to fungiska by Aspergillus species has not been studied.
| Trade Name | fungiska |
| Availability | Prescription only |
| Generic | Caspofungin |
| Caspofungin Other Names | Caspofungin, Caspofungina |
| Related Drugs | ciprofloxacin, fluconazole, Augmentin, amoxicillin / clavulanate, vancomycin, gentamicin, Diflucan, itraconazole, amphotericin b, voriconazole |
| Weight | 50mg, 70mg |
| Type | Powder, For Solution |
| Formula | C52H88N10O15 |
| Weight | Average: 1093.331 Monoisotopic: 1092.643062174 |
| Protein binding | 97% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Spimaco |
| Available Country | Saudi Arabia |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
fungiska is an echinocandin used to treat a variety of fungal infections.
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
fungiska is also used to associated treatment for these conditions: Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Infections, Fungal, Oropharyngeal Candidiasis, Peritonitis, Invasive, refractory Aspergillosis, Pleural space infections
How fungiska works
fungiska inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. beta-(1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase.
Toxicity
Side effects include rash, swelling, and nausea (rare)
Food Interaction
No interactions found.fungiska Drug Interaction
Unknown: aspirin, aspirin, sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprim, ubiquinone, ubiquinone, copper gluconate, copper gluconate, meperidine, meperidine, glycerin, glycerin, acetaminophen, acetaminophen, bioflavonoids, bioflavonoids, cholecalciferol, cholecalciferol, phytonadione, phytonadione
fungiska Disease Interaction
Elimination Route
92% tissue distribution within 36-48 hours after intravenous infusion
Half Life
9-11 hours
Clearance
- 12 mL/min [After single IV administration]
Elimination Route
After single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine.
Innovators Monograph
You find simplified version here fungiska
